FDA Approves Roche's Kidney Cancer Drug

by VR Sreeraman on  August 3, 2009 at 5:29 PM Drug News   - G J E 4
Medical authorities in the United States have approved the use of the drug Avastin to help combat the most common form of kidney cancer, the Swiss pharmaceutical giant Roche announced Monday.
 FDA Approves Roche's Kidney Cancer Drug
FDA Approves Roche's Kidney Cancer Drug

Avastin has been given the seal of approval by the Food and Drug Administration (FDA) to be used to treat metastatic renal cell carcinoma in combination with the drug Interferon Alpha, Roche said in a statement.

According to the results of the third phase of a clinical study, patients who used a combination of the two drugs lived nearly twice as long without their disease getting worse compared to those who only used Interferon Alpha.

"This underscores our belief in the important clinical benefits that Avastin delivers as we push forward with our ongoing research programmes in more than 30 tumour types," said William Burns, chief executive of Roche's pharmaceuticals division.

Kidney cancer is the eighth most common type of cancer in the US, accounting for some 13,000 people last year.

Avastin has been available since the end of 2007 in Europe as a first line of treatment against advanced kidney cancer.

The news comes after the European Commission last week approved the use of Avastin as a treatment against breast cancer.

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
Thank you for bringing up top news regarding Avastin and kidney cancer.
Has there been anywhere study comparing the efficacy of BAYER's prducts (Sorafenib) versus Avastub as first line treatment for kidney cancer??

Anat_Ronai Monday, August 3, 2009

You May Also Like